1/ In his book 📚 A World Without Email, Prof. Cal Newport advances the Attention Capital Principle productivity of the knowledge sector can be ⬆️ by identifying workflows that optimize the human brain’s 🧠 ability to add value to information (my paraphrase) #FutureOfWork

Focused on delivering for Delaware. On to the general. Blake Landro nytimes.com/2024/09/10/us/…

NRG GU-009/PREDICT-RT Intensification Arms completed accrual yesterday, 2 years ahead of schedule! Thank you NRG Oncology GU investigators and patients and let’s keep up the great momentum to accrue the De-Intensification Arms (24 vs 12 mos ADT) over the next year!

"The last government broke the NHS - until this morning we didn't know the full scale of the damage which is laid bare in the [Darzi] report," Keir Starmer says "The 2010s were a lost decade" for the health service, the PM adds Follow live bbc.in/47pD4BF

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun Tolan⁩ Alison Tree 💙⁩ ⁦Clive Peedell⁩ Dr. Andrew Loblaw⁩ ⁦Prof Emma Hall⁩ Prof Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

More evidence that #MedicareAdvantage is a major source of hospital denials despite evidence that way over 50% of denials are over turned on appeal. MA denials increased nearly 56% between ‘22-23! beckershospitalreview.com/finance/the-li…

Happy to announce that the PEACE 6 OligoPRESTO trial testing the role of metastasis directed therapy in hormone sensitive #ProstateCancer has completed accrual ahead of schedule. 550 patients randomized. Waiting now for data to mature.

#New General election poll - Post debate 🔵 Harris 50% (+5) 🔴 Trump 45% Last poll - 🔵 Harris +3 Morning Consult #C - 3204 LV - 9/12

Welcoming a new member to our clinical NGS test menu, joining MSK-IMPACT, MSK-Fusion, & MSK-ACCESS: MSK-REACT (Rapid Evaluation of Actionable Cancer Targets). Critical results in 3-4d. Kudos to test dev team led by Mark Ewalt. Memorial Sloan Kettering Cancer Center MSK Department of Pathology & Laboratory Medicine Michael Berger #LCSM

We deserve a new mayor. A mayor who cuts education, library budgets, and parks, who surrounds himself with criminals and alleged corruption up to the very top, does not deserve our trust. (1/2)

I’m hearing so many people cite conflict of interest as the reason physicians shouldn’t own hospitals. This also happens to be the main strategy the American Hospital Association used to lobby Congress to ban POHs in the Affordable Care Act, paving the way for the consolidated

Sat down at a Wilmington Brew Ha-Ha with Sen. Sarah McBride, who in eight weeks is likely to become the first transgender member of Congress. semafor.com/article/09/13/…

I was looking through photos from Tuesday wrapping my mind around the events of this week and after coming across this picture from just outside the polls at Dover High School, I couldn’t help but share it. More than five years ago, a mutual friend set me up on a “friend date”

Join MSK head and neck oncologist Dr. Winston Wong on 9/14 at #ESMO for his poster session on phase 2 trial of ozuriftamab vedotin (BA3021) in patients with recurrent or metastatic squamous cell #carcinoma of the head and neck (R/M SCCHN). Learn more ➡️ bit.ly/47nXGdB

Our view of the future of telemedicine in RadOnc. Huge potential for patients. But regulatory roadblocks remain. Great collaboration with Helen Hughes, Medical Director of the Office of Telemedicine Johns Hopkins Medicine, and Shannon M MacDonald. #radonc #MedTwitter MassGeneral News

We'd like to congratulate Alan Ho on his new role as Chief of the Head and Neck Oncology Service within the Division of Solid Tumor Oncology in the Department of Medicine at MSK. Learn more about Dr. Ho ➡️ bit.ly/3ZI1qVB #ESMO24

Sean McBride Pierre Blanchard, MD Herbert Loong, MBBS, FASCO ESMO - Eur. Oncology This is our umbrella protocol that is ongoing now clinicaltrials.gov/study/NCT05517…

Sean McBride Completely agree. Our phase II RCT (ENI versus INRT) should hopefully start enrolling in October...

You Need to Calm Down

Another ARPI in 1st line therapy for mHSPC: ARANOTE trial presented at #ESMO2024 & published simultaneously at Journal of Clinical Oncology Darolutamide improves all endpoints (rPFS, time to CRPC, time to pain, deep PSA response...), OS immature No safety concern (less fatigue with daro vs PBO!)